Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Universitaet Leipzig is active in the Biotechnology & Pharmaceuticals technology area, where it currently has 1 pending office action. This single pending matter represents the current focus of the university's patent prosecution efforts. A portfolio with only 1 pending action typically indicates a very specific or controlled set of active applications within the patent office, which may reflect a selective approach to patenting academic research or a focus on a single key discovery.
The prosecution process is highly centralized, involving 1 distinct examiner and 1 distinct art unit. METCALF, MATTHEW CURRAN is the busiest examiner for the university, currently overseeing 1 pending office action. Since this examiner is the only one currently reviewing the university's pending work, their individual examination style is the primary variable in the prosecution process. The involvement of only 1 distinct art unit suggests that the technical subject matter is concentrated within a specific biological or pharmaceutical niche. This allows for a streamlined legal strategy that addresses the specific technical standards of a single art unit and the preferences of one examiner, which can be advantageous for academic institutions with limited prosecution resources.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Multi-statute (no §101) | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| METCALF, MATTHEW CURRAN | 1 | 37.5% | +71.4% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18044948 | CHIMERIC SENSOR PROTEIN AND METHODS OF USE THEREOF | METCALF, MATTHEW CURRAN | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18044948 | CHIMERIC SENSOR PROTEIN AND METHODS OF USE THEREOF | METCALF, MATTHEW CURRAN | — |
| Art Unit | Apps |
|---|---|
| 1647 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18044948 | CHIMERIC SENSOR PROTEIN AND METHODS OF USE THEREOF | METCALF, MATTHEW CURRAN | 1647 | §103§112 | Non-Final OA | — | Pending | Mar 10, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialUniversitaet Leipzig has 1 pending office actions as of October 2026, spread across 1 art units and 1 examiners.
Matthew Curran Metcalf has the most, with 1 of Universitaet Leipzig's pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
